Glioma, Malignant Glioma of Brain, Recurrence Tumor
Conditions
Brief summary
A pilot study to determine the safety and efficacy of chimeric antigen receptor T cell (autologous T cells transduced with a lentiviral vector expressing chimeric antigen receptor with or without anti-PDL1 antibody) personalized immunotherapy for patients with recurrent malignant gliomas based on the expression of tumor specific/associated antigens (EGFRVIII, IL13Rα2, Her-2, EphA2, CD133, GD2).
Interventions
BIOLOGICALchimeric antigen receptor T cells
chimeric antigen receptor T cells expressing receptors specific for EGFRvIII, IL13Rα2, Her-2, CD133, EphA2, GD2, respectively
Sponsors
Beijing Mario Biotech Company
Hebei Senlang BIotech Company
Beijing HuiNengAn Biotech Company
Xuanwu Hospital, Beijing
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Voluntary informed consent for entry of trial; * Age greater than 18 years, and less than 70 years; * Pathologically confirmed recurrent malignant gliomas; * Tumor cells from resected tissue must be available for antigen testing (EGFRvIII, IL13Rα2, Her-2, CD133, EphA2, GD2) and at least one of the targets should be tested positively by immunohistochemistry study; * If the patient is on dexamethasone, the anticipated dose must be 4 mg/day or less for at least 5 days prior to apheresis. * Patients must have a Karnofsky performance status of greater than or equal to 70. * Life expectancy greater than 3 months; * Participants with adequate organ function as measured by: 1. White blood count greater than or equal to 2500/mm\^3; platelets greater than or equal to 100,000/mm\^3, hemoglobin greater than or equal to 10.0 g/dL; without transfusion or growth factor support 2. Aspartate transaminase (AST), Alanine transaminase (ALT), gamma glutamyl transpeptidase (GGT), lactic acid dehydrogenase (LDH), alkaline phosphatase within 2.5 x upper normal limit, and total bilirubin less than or equal to 2.0 mg/dL 3. Serum creatinine less than or equal to 1.5 x upper limit of normal 4. Coagulation tests prothrombin time (PT) and partial thromboplastin time (PTT) have to be within normal limits, unless the patient has been therapeutically anti-coagulated for previous venous thrombosis.
Exclusion criteria
* Female subjects of reproductive potential who are pregnant or lactating; * Previous treatment with any gene therapy products or other form immunotherapy; * Uncontrolled active infection. * Active or latent chronic hepatitis B \[detectable hepatitis B surface antigen (HBsAg)\] or active hepatitis C (positive serology \[hepatitis C virus Ab\]) infection. * HIV infection; * History of allergy or hypersensitivity to study product excipients (human serum albumin, Dimethyl sulfoxide, and Dextran 40); * Currently enrolled in other clinical trials;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events attributed to the administration of the chimeric antigen receptor T cells | 1 year | Determine the toxicity profile of the chimeric antigen receptor T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | 1 year | The objective response rate (ORR) is defined as the proportion of patients who achieve radiographic partial or complete response (PR or CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guideline. |
| clinical activity of chimeric antigen receptor T cells | 28 days | the number of infused chimeric antigen receptor T cells; |
Countries
China
Outcome results
None listed